国家放射与治疗临床医学研究中心,苏州工业园区东方华夏心血管健康研究院,潘文志,宋光远,刘先宝,李捷,陈莎莎

• 1:复旦大学附属中山医院
• 2:首都医科大学附属北京安贞医院
• 3:浙江大学医学院附属第二医院
• 4:广东省人民医院

摘要(Abstract)：

经导管主动脉瓣置换术（TAVR），又称经导管主动脉瓣置入术，是指将人工主动脉瓣在体外压缩组装后，经导管输送并置入到病变的主动脉瓣处，在功能上完成主动脉瓣置换的一种介入技术。我国分别在2015年[《经导管主动脉瓣置换术中国专家共识》（以下简称2015版）]和2020年[《经导管主动脉瓣置换术中国专家共识（2020更新版）》（以下简称2020更新版）]发布两个版本的TAVR中国专家共识。为及时更新行业对TAVR的认识，推进TAVR在我国更广泛、更规范、更高质量的应用，专家组编写了2025版专家共识。本共识对2020更新版的专家共识进行较多的更新，涵盖了主动脉瓣疾病流行病学、TAVR研究进展、适应证、操作规范及术后抗栓治疗、并发症防治、特殊病例处理及发展趋势等内容。本共识既结合国外的研究证据，参考国外指南，做到严谨、实证，又结合国内研究及实践，其内容更具有前沿性和实用性。

关键词(KeyWords)： 经导管主动脉瓣置换术;专家共识;适应证;操作规范

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 国家放射与治疗临床医学研究中心,苏州工业园区东方华夏心血管健康研究院,潘文志,宋光远,刘先宝,李捷,陈莎莎

参考文献(References)：

• [1] Nishimura RA,Otto CM,Bonow RO,et al.2014 AHA/ACC guideline for the management of patients with valvular heart disease:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2014,63(22):2438-2488.DOI:10.1016/j.jacc.2014.02.537.
• [2]Baumgartner H,Falk V,Bax JJ,et al.2017 ESC/EACTS guidelines for the management of valvular heart disease[J].Eur Heart J,2017,38(36):2739-2791.DOI:10.1093/eurheartj/ehx391.
• [3] Nishimura RA,Otto CM,Bonow RO,et al.2017AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines[J].Circulation,2017,135(25):e1159-e1195.DOI:10.1161/CIR.0000000000000503.
• [4] Otto CM,Nishimura RA,Bonow RO,et al.2020 ACC/AHA Guideline for the management of patients with valvular heart disease:executive summary:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J].J Am Coll Cardiol,2021,77(4):450-500.DOI:10.1016/j.jacc.2020.11.035.
• [5] Vahanian A,Beyersdorf F,Praz F,et al.2021 ESC/EACTS Guidelines for the management of valvular heart disease[J].Eur Heart J,2022,43(7):561-632.DOI:10.1093/eurheartj/ehab 3 9 5.
• [6]Praz F,Borger MA,Lanz J,et al.2025 ESC/EACTS Guidelines for the management of valvular heart disease[J].Eur Heart J,2025:ehaf194.DOI:10.1093/eurheartj/ehaf194.Online ahead of print.
• [7]中国医师协会心血管内科医师分会结构性心脏病专业委员会,中华医学会心血管病学分会结构性心脏病学组.经导管主动脉瓣置换术中国专家共识[J].中国介入心脏病学杂志,2015,23(12):661-667.DOI:10.3969/j.issn.1004-8812.2015.12.001.
• [8]中国医师协会心血管内科医师分会结构性心脏病专业委员会.经导管主动脉瓣置换术中国专家共识(2020更新版)[J].中国介入心脏病学杂志,2020,28(6):301-309.DOI:10.3969/j.issn.1004-8812.2020.06.001.
• [9]Yang Y,Wang Z,Chen Z,et al.Current status and etiology of valvular heart disease in China:a population-based survey[J].BMC Cardiovasc Disord,2021,21(1):339.DOI:10.1186/s12872-021-02154-8.
• [10]Jilaihawi H,Wu Y,Yang Y,et al.Morphological characteristics of severe aortic stenosis in China:imaging corelab observations from the first Chinese transcatheter aortic valve trial[J].Catheter Cardiovasc Interv,2015,85 Suppl 1:752-761.DOI:10.1002/ccd.25863.
• [11] Xu H,Liu Q,Cao K,et al.Distribution,characteristics,and management of older patients with valvular heart disease in China:China-DVD study[J].JACC Asia,2022,2(3):354-365.DOI:10.1016/j.jacasi.2021.11.013.
• [12]Li Y,Wei X,Zhao Z,et al.Prevalence and complications of bicuspid aortic valve in Chinese according to echocardiographic database[J].Am J Cardiol,2017,120(2):287-291.DOI:10.1016/j.amjcard.2017.04.025.
• [13]潘文志,李明飞,周达新,等.重度主动脉瓣狭窄患者二叶式主动脉瓣的超声心动图分析[J].中华心血管病杂志,2015,43(3):244-247.DOI:10.3760/cma.j.issn.0253-3758.2015.03.012.
• [14]Généreux P,Schwartz A,Oldemeyer JB,et al.Transcatheter aortic-valve replacement for asymptomatic severe aortic stenosis[J].N Engl J Med,2025,392(3):217-227.DOI:10.1056/NEJMoa2405880.
• [15]Kang DH,Park SJ,Lee SA,et al.Early surgery or conservative care for asymptomatic aortic stenosis[J].N Engl J Med,2020,382(2):111-119.DOI:10.1056/NEJMoa1912846.
• [16] Banovic M,Putnik S,Penicka M,et al.Aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis:the AVATAR trial[J].Circulation,2022,145(9):648-658.DOI:10.1161/CIRCULATIONAHA.121.057639.
• [17]Halim SA,Edwards FH,Dai D,et al.Outcomes of transcatheter aortic valve replacement in patients with bicuspid aortic valve disease:a report from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry[J].Circulation,2020,141(13):1071-1079.DOI:10.1161/CIRCULATIONAHA.119.0403 33.
• [18]Zahr F,Ramlawi B,Reardon MJ,et al.3-Year outcomes from the Evolut low risk TAVR bicuspid study[J].JACC Cardiovasc Interv,2024,17(14):1667-1675.DOI:10.1016/j.jcin.2024.05.017.
• [19]Forrest JK,Ramlawi B,Deeb GM,et al.Transcatheter aortic valve replacement in low-risk patients with bicuspid aortic valve stenosis[J].JAMA Cardiol,2021,6(1):50-57.DOI:10.100 1/jamacardio.2020.473 8.
• [20]Li YM,Xiong TY,Xu K,et al.Characteristics and outcomes following transcatheter aortic valve replacement in China:a report from China aortic valve transcatheter replacement registry(CARRY)[J].Chin Med J(Engl),2021,134(22):2678-2684.DOI:10.1097/CM9.0000000000001882.
• [21]Hong N,Pan W,Liu X,et al.Transcatheter aortic valve replacement for bicuspid vs.tricuspid aortic stenosis among patients at low surgical risk in China:from the multicenter national NTCVR database[J].J Clin Med,2023,12(1):387.DOI:10.3390/jcm12010387.
• [22]Zhou D,Yidilisi A,Fan J,et al.Three-year outcomes of transcatheter aortic valve implantation for bicuspid versus tricuspid aortic stenosis[J].Euro Intervention,2022,18(3):193-202.DOI:10.4244/EIJ-D-21-00734.
• [23]Li HD,Li WY,Li JL,et al.Long-term durability of transcatheter aortic valve prostheses in patients with bicuspid versus tricuspid aortic valve[J].J Am Heart Assoc,2024,13(21):e035772.DOI:10.1161/JAHA.124.035772.
• [24]Oettinger V,Hilgendorf I,Wolf D,et al.Treatment of pure aortic regurgitation using surgical or transcatheter aortic valve replacement between 2018 and 2020 in Germany[J].Front Cardiovasc Med,2023,10:1091983.DOI:10.3389/fcvm.2023.1091983.
• [25]Mentias A,Saad M,Menon V,et al.Transcatheter vs surgical aortic valve replacement in pure native aortic regurgitation[J].Ann Thorac Surg,2023,115(4):870-876.DOI:10.1016/j.athoracsur.2022.09.016.
• [26] Koch R,Inci E,Grubb K,et al.A comparison of thirty-day clinical and echocardiographic outcomes of patients undergoing transcatheter vs.surgical aortic valve replacement for native aortic insufficiency[J].Cardiovasc Revasc Med,2023,46:85-89.DOI:10.1016/j.carrev.2022.08.010.
• [27] Chen Y,Lu ZN,Yao J,et al.A novel anatomic classificationto guide transcatheter aortic valve replacement for pure aortic regurgitation[J].Echocardiography,2022,39(12):1571-1580.DOI:10.1111/echo.15490.
• [28]Xia F,Chen X,Weng Z,et al.Noncoronary Sinus Pivot Implantation(NCPI)strategy for transcatheter aortic valve replacement with self-expanding valve in pure native aortic regurgitation:a multicenter,registry study from the CCA database-NT CVR[J].Catheter Cardiovasc Interv,2025.DOI:10.1002/ccd.70183.Online ahead of print.
• [29]Yang L,Weng Z,Chen S,et al.Noncoronary sinus pivot implantation for transcatheter aortic valve replacement with selfexpanding valve for aortic regurgitation[J].JACC Asia,2025,5(7):884-894.DOI:10.1016/j.jacasi.2025.04.004.
• [30]中国医师协会心血管内科医师分会结构性心脏病学组.单纯主动脉瓣反流经股动脉主动脉瓣置换中国专家共识2023[J].中国介入心脏病学杂志,2023,31(11):801-809.DOI:10.3969/j.issn.1004-8812.2023.11.001.
• [31] Da-Wei L,Zi-Long W,Yan-Xing F,et al.Short-term outcomes of transcatheter aortic valve replacement in low-risk patients with pure severe aortic regurgitation[J].Am J Cardiol,2024,222:58-64.DOI:10.1016/j.amjcard.2024.04.056.
• [32]Garcia S,Ye J,Webb J,et al.Transcatheter treatment of native aortic valve regurgitation:the North American experience with a novel device[J].JACC Cardiovasc Interv,2023,16(16):1953-1960.DOI:10.1016/j.jcin.2023.05.018.
• [33] Adam M,Tamm AR,Wienemann H,et al.Transcatheter aortic valve replacement for isolated aortic regurgitation using a new self-expanding TAVR system[J].JACC Cardiovasc Interv,2023,16(16):1965-1973.DOI:10.1016/j.jcin.2023.07.038.
• [34] Vahl TP,Thourani VH,Makkar RR,et al.Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation(ALIGN-AR):a prospective,multicentre,single-arm study[J].Lancet,2024,403(10435):1451-1459.DOI:10.1016/S0140-6736(23)02806-4.
• [35] Mack MJ,Leon MB,Thourani VH,et al.Transcatheter aortic-valve replacement in low-risk patients at five years[J].N Engl J Med,2023,389(21):1949-1960.DOI:10.1056/NEJMoa2307447.
• [36]Makkar RR,Thourani VH,Mack MJ,et al.Five-year outcomes of transcatheter or surgical aortic-valve replacement[J].N Engl J Med,2020,382(9):799-809.DOI:10.1056/NEJMoa1910555.
• [37]Van Mieghem NM,Deeb GM,Sondergard L,et al.Self-expanding transcatheter vs surgical aortic valve replacement in intermediate-risk patients:5-year outcomes of the SURTAVI randomized clinical trial[J].JAMA Cardiol,2022,7(10):1000-1008.DOI:10.1001/jamacardio.2022.2695.
• [38]Thy regod HGH,J??rgensen TH,Ihlemann N,et al.Transcatheter or surgical aortic valve implantation:10-year outcomes of the NOTION trial[J].Eur Heart J,2024,45(13):1116-1124.DOI:10.1093/eurheartj/ehae043.
• [39]Baron SJ,Ryan MP,Chikermane SG,et al.Long-term risk of reintervention after transcatheter aortic valve replacement[J].Am Heart J,2024,267:44-51.DOI:10.1016/j.ahj.2023.10.002.
• [40] Tam DY,Dharma C,Rocha RV,et al.Transcatheter ViV versus redo surgical AVR for the management of failed biological prosthesis:early and late outcomes in a propensity-matched cohort[J].JACC Cardiovasc Interv,2020,13(6):765-774.DOI:10.1016/j.jcin.2019.10.030.
• [41] SáMBPO,Van den Eynde J,Simonato M,et al.Valve-invalve transcatheter aortic valye replacement versus redo surgical aortic valve replacement:an updated meta-analysis[J].JACC Cardiovasc Interv,2021,14(2):211-220.DOI:10.1016/j.jcin.2020.10.020.
• [42]Edwards FH,Cohen DJ,O'Brien SM,et al.Development and validation of a risk prediction model for in-hospital mortality after transcatheter aortic valve replacement[J].JAMA Cardiol,2016,1(1):46-52.DOI:10.1001/jamacardio.2015.0326.
• [43] Yamamoto M,Otsuka T,Shimura T,et al.Clinical risk model for predicting 1-year mortality after transcatheter aortic valve replacement[J].Catheter Cardiovasc Interv,2021,97(4):E544-E551.DOI:10.1002/ccd.29130.
• [44]中国医师协会放射医师分会心血管学组,国家心血管病专业质控中心心血管影像质控专家工作组,中国研究型医院学会心血管影像专业委员会.经导管主动脉瓣置换术CT规范化评估中国专家共识[J].中华放射学杂志,2024,58(6):576-586.DOI:10.3760/cma.j.cn112149-20231214-00470.
• [45] Wood DA,Lauck SB,Cairns JA,et al.The Vancouver3M(Multidisciplinary,Multimodality,But Minimalist)clinical pathway facilitates safe next-day discharge home at low-,medium-,and high-volume transfemoral transcatheter aortic valve replacement centers:the 3M TAVR study[J].JACC Cardiovasc Interv,2019,12(5):459-469.DOI:10.1016/j.jcin.2018.12.020.
• [46]Liu X,He Y,Zhu Q,et al.Supra-annular structure assessment for self-expanding transcatheter heart valve size selection in patients with bicuspid aortic valve[J].Catheter Cardiovasc Interv,2018,91(5):986-994.DOI:10.1002/ccd.27467.
• [47]Zhang Y,Pan WZ,Guan LH,et al.Small balloon strategy associated with low pacemaker implantation rate after self-expanding transcatheter valve implantation[J].World J Emerg Med,2021,12(1):48-53.DOI:10.5847/wjem.j.1920-8642.2021.01.008.
• [48]Brouwer J,Nijenhuis VJ,Delewi R,et al.Aspirin with or without Clopidogrel after transcatheter aortic-valve implantation[J].N Engl J Med,2020,383(15):1447-1457.DOI:10.1056/NEJMoa2017815.
• [49]Nijenhuis VJ,Brouwer J,Delewi R,et al.Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation[J].N Engl J Med,2020,382(18):1696-1707.DOI:10.1056/NEJMoa1915152.
• [50]Dangas GD,Tijssen JGP,W??hrle J,et al.A controlled trial of rivaroxaban after transcatheter aortic-valve replacement[J].N Engl J Med,2020,382(2):120-129.DOI:10.1056/NEJMoa1911425.
• [51]Généreux P,Piazza N,Alu MC,et al.Valve Academic Research Consortium 3:updated endpoint definitions for aortic valve clinical research[J].J Am Coll Cardiol,2021,77(21):2717-2746.DOI:10.1016/j.jacc.2021.02.038.
• [52]Siontis GC,Jüni P,Pilgrim T,et al.Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR:a meta-analysis[J].J Am Coll Cardiol,2014,64(2):129-140.DOI:10.1016/j.jacc.2014.04.033.
• [53]Gada H,Khalil RF,Chetcuti SJ,et al.30-day and 1-year outcomes from the optimize PRO TAVR Evolut FX addendum study[J].JACC Cardiovasc Interv,2025,18(16):2004-2017.DOI:10.1016/j.jcin.2025.06.021.
• [54]Grubb KJ,Gada H,Mittal S,et al.Clinical impact of standardized TAVR technique and care pathway:insights from the optimize PRO study[J].JACC Cardiovasc Interv,2023,16(5):558-570.DOI:10.1016/j.jcin.2023.01.016.
• [55] Sammour Y,Krishnaswamy A,Kumar A,et al.Incidence,predictors,and implications of permanent pacemaker requirement after transcatheter aortic valve replacement[J].JACC Cardiovasc Interv,2021,14(2):115-134.DOI:10.1016/j.jcin.2020.09.063.
• [56]Rodés-Cabau J,Ellenbogen KA,Krahn AD,et al.Management of conduction disturbances associated with transcatheter aortic valve replacement:JACC scientific expert panel[J].J Am Coll Cardiol,2019,74(8):1086-1106.DOI:10.1016/j.j acc.2019.07.014.
• [57]Lilly SM,De shmukh A J,Epstein AE,et al.2020 ACC expert consensus decision pathway on management of conduction disturbances in patients undergoing transcatheter aortic valve replacement:a report of the American College of Cardiology Solution Set Oversight Committee[J].J Am Coll Cardiol,2020,76(20):2391-2411.DOI:10.1016/j.jacc.2020.08.050.
• [58]Badertscher P,Knecht S,Zeljkovic I,et al.Management of conduction disorders after transcatheter aortic valve implantation:results of the EHRA survey[J].Europace,2022,24(7):1179-1185.DOI:10.1093/europace/euac027.
• [59]Wang B,Mei Z,Ge X,et al.Comparison of outcomes of self-expanding versus balloon-expandable valves for transcatheter aortic valve replacement:a meta-analysis of randomized and propensity-matched studies[J].BMC Cardiovasc Disord,2023,23(1):382.DOI:10.1186/s12872-023-03397-3.
• [60]Synetos A,Ktenopoulos N,Katsaros O,et al.Paravalvular leak in transcatheter aortic valve implantation:a review of current challenges and future directions[J].J Cardiovasc Dev Dis,2025,12(4):125.DOI:10.3390/jcdd12040125.
• [61]Wang H,Wu X,Zhang H,et al.Risk factors and predictive model for moderate to severe perivalvular leakage following transcatheter aortic valve replacement[J].Am J Transl Res,2024,16(12):7563-7572.DOI:10.62347/VRXS6310.
• [62]van Wely M,Rooijakkers M,Stens N,et al.Paravalvular regurgitation after transcatheter aortic valve replacement:incidence,quantification,and prognostic impact[J].Eur Heart J Imaging Methods Pract,2024,2(2):qyae040.DOI:10.1093/ehjimp/qyae040.
• [63]Ibrahim H,Chaus A,Alkhalil A,et al.Coronary artery obstruction after transcatheter aortic valve implantation:past,present,and future[J].Circ Cardiovasc Interv,2024,17(6):e012827.DOI:10.1161/CIRCINTERVENTIONS.123.012827.
• [64]Kitamura M,Wilde J,Dumpies O,et al.Risk assessment of coronary obstruction during transcatheter aortic valve replacement:insights from post-BA SILICA computed tomography[J].JACC Cardiovasc Interv,2022,15(5):496-507.DOI:10.1016/j.j cin.2022.01.003.
• [65]Mangieri A,Richter I,Gitto M,et al.Chimney stenting vs BASILICA for prevention of acute coronary obstruction during transcatheter aortic valve replacement[J].JACC Cardiovasc Interv,2024,17(6):742-752.DOI:10.1016/j.jcin.2024.01.007.
• [66]Tagliari AP,Petersen Saadi R,Medronha EF,et al.The use of BASILICA technique to prevent coronary obstruction in a TAVI-TAVI procedure[J].J Clin Med,2021,10(23):5534.DOI:10.3390/jcm10235534.
• [67]Palmerini T,Chakravarty T,Saia F,et al.Coronary protection to prevent coronary obstruction during TAVR:a multicenter international registry[J].JACC Cardiovasc Interv,2020,13(6):739-747.DOI:10.1016/j.jcin.2019.11.024.
• [68]Grossman PM,Sukul D,Lall SC,et al.The relationship between hospital stroke center designation and TVT reported stroke:the michigan TAVR experience[J].JACC Cardiovasc Interv,2023,16(2):168-176.DOI:10.1016/j.jcin.2022.10.020.
• [69]Kapadia SR,Makkar R,Leon M,et al.Cerebral embolic protection during transcatheter aortic-valve replacement[J].N Engl J Med,2022,387(14):1253-1263.DOI:10.1056/NEJMoa2204961.
• [70]Shekhar S,Isogai T,Agrawal A,et al.Outcomes and predictors of stroke after transcatheter aortic valve replacement in the cerebral protection device era[J].J Am Heart Assoc,2024,13(15):e034298.DOI:10.1161/JAHA.124.034298.
• [71] Gorla R,Tua L,D'Errigo P,et al.Incidence and predictors of 30-day and 6-month stroke after TAVR:insights from the multicenter OBSERVANTⅡstudy[J].Catheter Cardiovasc Interv,2023,102(6):1122-1131.DOI:10.1002/ccd.30848.
• [72] Castelo A,Grazina A,Teixeira B,et al.Outcomes and predictors of periprocedural stroke after transeatheter aortic valve implantation[J].J Stroke Cerebrovasc Dis,2023,32(5):107054.DOI:10.1016/j.jstrokecerebrovasdis.2023.107054.
• [73]Misra S,Khokhar AA,Lucarelli C,et al.Incidence,risk factors,and stroke prevention during transcatheter aortic valve implantation[J].Rev Cardiovasc Med,2025,26(4):26867.DOI:10.31083/RCM26867.
• [74] Pan E,Kroon HG,Tonino PAL,et al.Impact of sheath type on vascular and bleeding complications after transcatheter aortic valve replacement:a post hoc analysis from the MARVEL registry study[J].Catheter Cardiovasc Interv,2025,105(4):787-794.DOI:10.1002/ccd.31396.
• [75]Kaur S,Nagaraja V,Schoenhagen P,et al.Outcomes of Cardiac tamponade post-transcatheter aortic valve replacement:results from a Tertiary Cardiac Center[J].Struct Heart,2024,9(2):100356.DOI:10.1016/j.shj.2024.100356.
• [76]Chopko TC,Afoke JN,Khan FW,et al.Bioprosthetic valve fracture for transcatheter aortic valve-in-valve replacement:a systematic literature review[J].Ann Thorac Surg,2025,120(5):817-825.DOI:10.1016/j.athoracsur.2025.01.009.
• [77] Reddy P,Cohen J,Chitturi KR,et al.What are the implications of choosing a TAVR-first strategy in the lifetime management of aortic stenosis?:a critical review of TAVR-Explant-and Redo-TAVR[J].Circ Cardiovasc Interv,2025,18(2):e014882.DOI:10.1161/CIRCINTERVENTIONS.124.014882.
• [78]Windecker S,Tomii D,Planning for the future:CT-Based insights into Redo-TAVR and lifetime aortic valve care[J].JACC Cardiovasc Interv,2025,18(9):1186-1189.DOI:10.1016/j.jcin.2025.04.005.
• [79]Krishnamoorthy P,Onishi T,Zaid S,et al.CT and fluoroscopic analyses of valve expansion in redo-TAVR:a first-in-human report[J].JACC Cardiovasc Interv,2025,18(16):1971-1985.DOI:10.1016/j.jcin.2025.06.017.
• [80] Yang L,Chen S,Zhang X,et al.Comparisons of noncoronary sinus pivot implantation(NCPI)and conventional method for transcatheter aortic valve replacement with self-expanding valve in pure aortic regurgitation(PAR)[J],Catheter Cardiovasc Interv,2024,103(7):1093-1100.DOI:10.1002/ccd.31064.
• [81]Khalefa BB,Gonnah AR,Yassin MNA,et al.Impact of aorticangulation on outcomes in transcatheter aortic valve replacement with balloon-expandable and self-expanding valves:a sy stematic review and meta-analysis[J].Cardiovasc Interv Ther,2025,40(4):746-766.DOI:10.1007/s 12928-025-01169-8.
• [82] Généreux P,Pibarot P,Redfors B,et al.Staging classification of aortic stenosis based on the extent of cardiac damage[J].Eur Heart J,2017,38(45):3351-3358.DOI:10.1093/eurheartj/ehx381.
• [83]Vollema EM,Amanullah MR,Ng ACT,et al.Staging cardiac damage in patients with symptomatic aortic valve stenosis[J].J Am Coll Cardiol,2019,74(4):538-549.DOI:10.1016/j.jacc.2019.05.048.
• [84]Amano M,Izumi C,Taniguchi T,et al.Impact of concomitant tricuspid regurgitation on longterm outcomes in severe aortic stenosis[J].Eur Heart J Cardiovasc Imaging,2019,20(3):353-360.DOI:10.1093/ehjci/jey105.
• [85] Doldi PM,Steffen J,Gehlich A,et al.Interplay of aortic stenosis flow groups and mitral regurgitation etiology in patients undergoing TAVR[J].Eur Heart J Cardiovasc Imaging,2025,jeaf254.DOI:10.1093/ehjci/jeaf254.
• [86]Ye C,Ma X,Shi B,et al.Acute kidney injury and in-hospital outcomes after transcatheter aortic valve replacement in patients without chronic kidney disease:insights from the national inpatient sample[J].BMC Cardiovasc Disord,2024,24(1):706.DOI:10.1186/s12872-024-04303-1.
• [87]Soodi D,Yeung P,Umukoro P,et al.The potential renal protective effect of transcatheter aortic valve replacement[J].Cureus,2025,17(3):e80465.DOI:10.7759/cureus.80465.
• [88]Lorente-Ros M,Das S,Malik A,et al.In-hospital outcomes of transcatheter aortic valve replacement in patients with chronic and end-stage renal disease:a nationwide database study[J].BMC Cardiovasc Disord,2024,24(1):21.DOI:10.1186/s12872-023-03684-z.
• [89]Faroux L,Guimaraes L,Wintzer-Wehekind J,et al.Coro